Impact of Post-Progression Therapy (PPT) on Survival in AVF2107, a phase III trial of bevacizumab (AVASTIN™) in the first-line treatment of metastatic colorectal cancer

被引：0
|
作者：
Hedrick, Eric [1 ]
Hurwitz, H. [2 ]
Sarkar, S.
Griffing, S.
Grothey, A. [3 ]
机构：
[1] Genentech Inc, Hematol Oncol, Summit, NJ USA
[2] Duke Univ, Durham, NC USA
[3] Mayo Clin, Rochester, MN USA
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [41] Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
    Vrdoljak, E.
    Marschner, N.
    Zielinski, C.
    Gligorov, J.
    Cortes, J.
    Puglisi, F.
    Aapro, M.
    Fallowfield, L.
    Fontana, A.
    Inbar, M.
    Kahan, Z.
    Welt, A.
    Levy, C.
    Brain, E.
    Pivot, X.
    Putzu, C.
    Gonzalez Martin, A.
    de Ducla, S.
    Easton, V.
    von Minckwitz, G.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2046 - 2052
  • [42] Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase III noninferiority trial (SAKK 41/06).
    Koeberle, Dieter
    Betticher, Daniel C.
    Von Moos, Roger
    Dietrich, Daniel
    Brauchli, Peter
    Baertschi, Daniela
    Matter-Walstra, Klazien
    Winterhalder, Ralph C.
    Borner, Markus M.
    Anchisi, Sandro
    Moosmann, Peter
    Kollar, Attila
    Saletti, Piercarlo
    Roth, Arnaud
    Frueh, Martin
    Kueng, Marc
    Popescu, Razvan A.
    Schacher, Sabina
    Hess, Viviane
    Herrmann, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
  • [44] Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    J Barriuso
    British Journal of Cancer, 2011, 104 : 226 - 226
  • [45] An update on treatment advances for the first-line therapy of metastatic colorectal cancer
    Lee, James J.
    Chu, Edward
    CANCER JOURNAL, 2007, 13 (05): : 276 - 281
  • [46] Comment on 'Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer'
    Molina-Garrido, M. J.
    Guillen-Ponce, C.
    BRITISH JOURNAL OF CANCER, 2011, 104 (01) : 224 - 225
  • [47] Bevacizumab with chemotherapy for the first-line treatment of metastatic colorectal cancer: "NCI Slovakia" results
    Dolinsky, J.
    Salek, T.
    Hlavata, Z.
    Ivancova, H.
    Risnyovszka, Z.
    Mardiak, J.
    Koza, I
    ANNALS OF ONCOLOGY, 2006, 17 : 70 - 70
  • [48] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study
    Antonuzzo, Lorenzo
    Giommoni, Elisa
    Pastorelli, Davide
    Latiano, Tiziana
    Pavese, Ida
    Azzarello, Domenico
    Aieta, Michele
    Pastina, Ilaria
    Di Fabio, Francesca
    Bertolini, Alessandro
    Corsi, Domenico Cristiano
    Mogavero, Selene
    Angelini, Valentina
    Pazzagli, Mario
    Di Costanzo, Francesco
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (23) : 7281 - 7288
  • [49] Progression-Free Survival in Bevacizumab-Based First-Line Treatment for Patients With Metastatic Colorectal Cancer: Is It a Really Good End Point?
    Montagnani, Francesco
    Migali, Cristina
    Fiorentini, Giammaria
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : E132 - E133
  • [50] Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
    M J Molina-Garrido
    C Guillén-Ponce
    British Journal of Cancer, 2011, 104 : 224 - 225
12345